MORPHOSYS AG O.N. news, videos and press releases - Page 11
For more news please use our advanced search feature.
MORPHOSYS AG O.N. - More news...
MORPHOSYS AG O.N. - More news...
- DGAP-News: MorphoSys's Licensing Partner GSK Initiates Phase 3 Clinical Program With Otilimab (MOR103/GSK3196165) in Rheumatoid Arthritis; MorphoSys Updates its Financial Guidance for 2019
- DGAP-Adhoc: Ad hoc: MorphoSys Increases Financial Guidance for 2019 Following a Milestone Payment for Antibody Otilimab (MOR103/GSK3196165) by GSK
- Ad hoc: MorphoSys Increases Financial Guidance for 2019 Following a Milestone Payment for Antibody Otilimab (MOR103/GSK3196165) by GSK
- MorphoSys's Licensing Partner GSK Initiates Phase 3 Clinical Program With Otilimab (MOR103/GSK3196165) in Rheumatoid Arthritis; MorphoSys Updates its Financial Guidance for 2019
- CORRECTION: Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
- DGAP-Adhoc: Correction of a release from 24/06/2019, 20:36 CET/CEST - Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
- DGAP-News: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
- DGAP-Adhoc: Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
- MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
- MorphoSys Presents Primary Analysis Data from L-MIND Study of Tafasitamab (MOR208) in combination with Lenalidomide in r/r DLBCL at ICML 2019
- DGAP-News: MorphoSys Presents Primary Analysis Data from L-MIND Study of Tafasitamab (MOR208) in combination with Lenalidomide in r/r DLBCL at ICML 2019
- DGAP-News: MorphoSys's Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (Tremfya(R)) in Adults with Active Psoriatic Arthritis
- DGAP-News: MorphoSys to Present at Upcoming Investor Conferences
- MorphoSys to Present at Upcoming Investor Conferences
- DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2019
- MorphoSys AG Reports Outcome of Annual General Meeting 2019
- DGAP-News: MorphoSys AG: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity
- DGAP-Adhoc: MorphoSys AG: Ad hoc: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity
- DGAP-News: MorphoSys AG Reports First Quarter 2019 Results
- MorphoSys AG Reports First Quarter 2019 Results
- DGAP-News: Invitation to MorphoSys Q1 2019 Conference Call on May 8, 2019
- Invitation to MorphoSys Q1 2019 Conference Call on May 8, 2019
- DGAP-News: MorphoSys and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical Study of MOR202/TJ202 in Multiple Myeloma
- MorphoSys and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical Study of MOR202/TJ202 in Multiple Myeloma
- DGAP-News: MorphoSys and Galapagos Announce Initiation of GECKO Phase 2 Study with MOR106 in Atopic Dermatitis Patients
- DGAP-News: MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Familial Adenomatous Polyposis
- DGAP-News: MorphoSys Nominates New Candidate for Supervisory Board
- MorphoSys Nominates New Candidate for Supervisory Board
- DGAP-News: MorphoSys to Present at Upcoming Investor Conferences
- DGAP-News: Dr. Sarah Fakih joins MorphoSys as Head of Corporate Communications and Investor Relations
